# Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

> **NCT04091126** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 118 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04091126
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-18
- **Primary completion:** 2025-06-02
- **Final completion:** 2026-12-31
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091126, "Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04091126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*